GSK Beefs-Up Benefit Data For “Approvable” OTC Weight-Loss Drug Alli
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline is bolstering its data on low-dose orlistat with several studies connecting the weight-loss drug to a reduction in risk factors associated with co-morbid diseases